A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers

Inclusion Criteria: 1. Men and women, 18 years or older, with advanced, relapsed or refractory solid tumors, Multiple Myeloma (MM) or non-Hodgkin's lymphoma (NHL) in Part A. In Part B, relapsed and/or refractory CD20-positive NHL subjects only. 2. At least one site of measurable disease in subjects with solid tumors and NHL. 3. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1. 4. Subjects must have adequate hematopoietic, liver, renal and coagulation function as assessed by specific laboratory criteria. 5. Females and males must agree to contraceptive methods and avoid conceiving throughout the study, and for up to 8 weeks following the last dose of CC-90002. If participating in Part B, females of child bearing potential should continue to use effective contraceptive methods for 12 months following treatment with rituximab Exclusion Criteria: 1. High grade lymphomas (Burkitts or lymphoblastic), plasma cell leukemia. 2. High grade, rapidly proliferative solid tumors (eg, small cell lung cancer, germ cell tumors, neuroblastoma) with extensive tumor burden. 3. Symptomatic central nervous system involvement. 4. Impaired cardiac function or clinically significant cardiac disease. 5. Prior Red blood cell (RBC) transfusion \< 3 months prior to starting CC-90002 (Part A only). 6. Prior autologous stem cell transplant ≤ 3 months prior to starting CC-90002. 7. Prior allogeneic stem cell transplant with either standard or reduced intensity conditioning ≤ 6 months prior to starting CC-90002. 8. Prior systemic cancer-directed treatments or investigational modalities ≤ 5 half lives or 4 weeks prior to starting CC-90002, whichever is shorter. 9. Major surgery ≤ 2 weeks prior to starting CC-90002. 10. Pregnant or nursing females. 11. Known HIV infection. 12. Known chronic, active hepatitis B or C (HBV/HCV) infection. 13. Ongoing treatment with chronic, therapeutic dosing of anti-coagulants. 14. History of autoimmune hemolytic anemia or autoimmune thrombocytopenia. 15. History of concurrent second cancers requiring active, ongoing systemic treatment. concurrent second cancers requiring active, ongoing systemic treatment.